Boras Ivan, Lazić Ratimir, Gabrić Nikica, Lukić Marko, Dekaris Iva
Universitiy Eye Clinic "Svjetlost", Zagreb, Croatia.
Coll Antropol. 2011 Sep;35 Suppl 2:15-8.
Diabetic macular edema is the leading cause of moderate visual deterioration in patients with diabetic retinopathy. Ranibizumab) blocks vascular endothelial growth factor (VEGF) induced hyperpermeability of blood vessels. In this prospective case series we investigated the efficacy and safety of anti-VEGF treatment in reduction of central retinal thickness (CRT) and improvement in visual acuity (VA) in patients with diabetic macular edema (DME). 9 patients were followed up for 6 months and treated monthly with intravitreal ranibizumab. VA and CRT were measured at each visit. Treatment was discontinued as the peak improvement of either parameter was reached and reinstituted in case of deterioration/recurrence of edema. Study endpoints included: VA using ETDRS chart, CRT and number of injections at 6 months. Mean VA from all 9 patients increased by 0.3 lines of logMAR (p < 0.05 compared to baseline), and CRT decreased from 515 +/- 123 microm to 310 +/- 110 microm. The improvement of VA after ranibizumab injection was in correlation with a decrease in CRT. Mean of 4 injections were needed to control the disease during the follow-up period. Ranibizumab treatment was effective in VA and reducing CRT. Several injections were needed to control the disease. Regular OCT examinations and retreatment are advised in order to maintain initially reached VA.
糖尿病性黄斑水肿是糖尿病视网膜病变患者中度视力下降的主要原因。雷珠单抗可阻断血管内皮生长因子（VEGF）诱导的血管高通透性。在这个前瞻性病例系列中，我们研究了抗VEGF治疗对糖尿病性黄斑水肿（DME）患者降低中心视网膜厚度（CRT）和提高视力（VA）的疗效和安全性。9例患者随访6个月，每月接受玻璃体内注射雷珠单抗治疗。每次就诊时测量VA和CRT。当任一参数达到峰值改善时停止治疗，若水肿恶化/复发则重新开始治疗。研究终点包括：使用ETDRS视力表测量的VA、CRT以及6个月时的注射次数。所有9例患者的平均VA提高了0.3个logMAR行（与基线相比，p<0.05），CRT从515±123微米降至310±110微米。雷珠单抗注射后VA的改善与CRT的降低相关。随访期间平均需要4次注射来控制病情。雷珠单抗治疗在改善VA和降低CRT方面有效。需要多次注射来控制病情。建议定期进行OCT检查和再次治疗，以维持最初达到的VA。
